Compare Gilead Sciences, Inc. (GILD) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs ProShares UltraPro QQQ ETF — how do they compare? Gilead Sciences, Inc. trades at $135.88 (market cap $163.51B), while ProShares UltraPro QQQ ETF trades at $70.27. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while ProShares UltraPro QQQ ETF pays none. Which is the better fit depends on your goals.
| GILD | TQQQ | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $155.80 | $87.22 |
52-Week Low | $108.22 | $37.89 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
TQQQ is trading at $71.65, down 4.49% on the day amid a bearish technical outlook with moving averages signaling caution. The leveraged ETF faces scrutiny over its daily compounding costs and volatility amplification risks. Recent news highlights concerns about leveraged ETFs potentially increasing market instability while acknowledging their potential for significant returns during bull markets.
The outlook remains clouded by structural risks inherent to daily reset leverage, with potential for amplified losses during market downturns. While long-term performance has been strong during tech rallies, the 81% drawdown in 2022 versus the Nasdaq's 33% decline underscores the asymmetric risk profile. Current bearish technical signals suggest near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
